Research
Hormonal
Nutritional ketosis (via ketogenic diet or fasting) induces a hormetic adaptive response that improves cellular resilience, reduces oxidative/inflammatory stress, and protects organs like the heart and brain, primarily through the activation of Nrf2, sirtuins, and AMPK.
Adopting a ketogenic diet or fasting induces ketone bodies, which act as a signal to your cells. This signal triggers a protective upgrade (hormesis) involving Nrf2 and sirtuins, improving your mitochondria and reducing inflammation. It is not just about burning fat; it is about training your cells to handle stress better.
ModerateSupportsMEDIUM confidence
We conclude that the increased synthesis and use of ketone bodies as ancillary fuel during periods of deficient food supply and low insulin levels causes oxidative stress in the mitochondria and that the latter initiates a protective (hormetic) response which allows cells to cope with increased oxidative stress and lower energy availability.
Why this rating
The paper is a review citing animal models and cell cultures; clinical data is mentioned but less mechanistic.
Source
Ketone bodies: from enemy to friend and guardian angel
Hubert Kolb et al. · BMC Medicine · 2021
DOI 10.1186/s12916-021-02185-0
narrative_reviewCited 335×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Ketogenic diets result in significantly greater weight loss and improvements in metabolic markers (insulin, HbA1c) compared to standard low-fat or non-ketogenic calorie-restricted diets in overweight or obese individuals, particularly those with type 2 diabetes.Good
- Ketone bodies (specifically beta-hydroxybutyrate) act as signaling molecules that inhibit histone deacetylases (HDACs) and promote histone acetylation, thereby altering gene expression to support anti-oxidant and anti-inflammatory pathways.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →